Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life

INTRODUCTION: Sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) protect type 2 diabetic (T2D) patients from cardiovascular events, but no trial has directly compared their cardiovascular effects. We aimed to address this gap using real-world d...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMJ Open Diabetes Res Care
Egile Nagusiak: Longato, Enrico, Di Camillo, Barbara, Sparacino, Giovanni, Gubian, Lorenzo, Avogaro, Angelo, Fadini, Gian Paolo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Cardiovascular and Metabolic Risk
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7319723/
https://ncbi.nlm.nih.gov/pubmed/32591373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2020-001451
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak